Indivior plc (INDV) USD0.1
Indivior PLC is a United Kingdom-based pharmaceutical company. The Company is engaged in developing medicines to treat addiction and serious mental illnesses. It focuses to build a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as new therapies to address the needs of people suffering from alcohol, stimulant and cannabis use disorders. Its pipeline products include INDV-3000 - Selective Dopamine D3-receptor Antagonist, RBP-6000 - Buprenorphine XR injection, Buprenorphine/ Naloxone Sublingual Film, Buprenorphine/ Naloxone Sublingual Tablet and Buprenorphine Sublingual Tablet, among others. Its portfolio of products is available in more than 40 countries.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.